FDA approves Regeneron's Livsayis for generalised myasthenia gravis
The FDA approved Regeneron's Livsayis (cemdisiran) to treat generalised myasthenia gravis in adults with anti-AChR antibodies. The therapy showed significant improvement in clinical trials, with a 4.5-point improvement in daily living scores versus 2.2 for placebo. Regeneron's George Yancopoulos called it a milestone for neurology and siRNA therapy. The EU is reviewing the treatment, with a decision expected in late 2027.
How this was made
The 30-second read
Why it matters
The approval validates Regeneron's neurology pipeline and may accelerate further RNA‑based product launches.
Market read
First FDA‑approved siRNA therapy for a neurological disease, likely to move Regeneron's stock and influence the RNA therapeutic space.
What to watch
Reimbursement rates and competition from other myasthenia gravis treatments could temper revenue growth.
Background
Regeneron partners with Alnylam on the siRNA platform; the drug targets complement component factor 5.
Market effects
Strengthens the biotech/siRNA sector and may boost peers developing RNA therapeutics.
U.S. biotech market gains from a high‑profile FDA approval.
Highlights FDA's openness to RNA therapies, potentially influencing global biotech valuations.
Counterpoint
If the market has already priced in the approval, the stock may see limited upside.
Key entities
- CompanyRegeneron Pharmaceuticals
US biotech firm developing Livsayis.
- CompanyAlnylam
Partner in the siRNA technology platform.




